GenSight Biologics S.A. (GSGTF)
USD 0.24
(-92.26%)
USD 0.24
(-92.26%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3 Million EUR | 19.82% |
| 2022 | 2.76 Million USD | -53.92% |
| 2021 | 5.99 Million USD | 11.54% |
| 2020 | 5.37 Million USD | 584.22% |
| 2019 | 785.74 Thousand USD | -82.99% |
| 2018 | 4.61 Million EUR | 10.69% |
| 2017 | 4.17 Million EUR | 41.68% |
| 2016 | 2.94 Million EUR | -20.74% |
| 2015 | 3.71 Million EUR | 178.39% |
| 2014 | 1.33 Million EUR | 6.69% |
| 2013 | 1.25 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.16 Million USD | 0.0% |
| 2023 Q2 | 1.69 Million USD | 0.0% |
| 2023 Q4 | 1.6 Million USD | 0.0% |
| 2023 FY | 3.31 Million USD | 19.82% |
| 2022 FY | 2.76 Million USD | -53.92% |
| 2022 Q2 | 3.2 Million USD | 0.0% |
| 2021 FY | 5.99 Million USD | 11.54% |
| 2021 Q2 | 6.6 Million USD | 0.0% |
| 2020 Q4 | 4.51 Million USD | 0.0% |
| 2020 FY | 5.37 Million USD | 584.22% |
| 2020 Q2 | 786.2 Thousand USD | 0.0% |
| 2019 FY | 785.74 Thousand USD | -82.99% |
| 2019 Q2 | -632.03 Thousand USD | 0.0% |
| 2019 Q4 | 785.74 Thousand USD | 0.0% |
| 2018 Q2 | -163.45 Thousand USD | 0.0% |
| 2018 Q4 | -200.05 Thousand USD | 0.0% |
| 2018 FY | 4.61 Million EUR | 10.69% |
| 2017 FY | 4.17 Million EUR | 41.68% |
| 2016 FY | 2.94 Million EUR | -20.74% |
| 2015 FY | 3.71 Million EUR | 178.39% |
| 2014 FY | 1.33 Million EUR | 6.69% |
| 2013 FY | 1.25 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 9.61 Million USD | 68.786% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 2514.467% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 97.481% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 1038.947% |
| Qrons Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 6316.457% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 123101.23% |
| BioStem Technologies, Inc. | 15.42 Million USD | 80.551% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -1599.139% |
| CSL Limited | 7.56 Billion USD | 99.96% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 111.629% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 74.372% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -2035.231% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 79.999% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -96611.799% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 69.369% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -4464.265% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 8884.773% |
| Mesoblast Limited | -35.16 Million USD | 108.53% |
| Marizyme, Inc. | 457.7 Thousand USD | -555.448% |
| Genus plc | 178.7 Million USD | 98.321% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 98.637% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -4721.136% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -631.413% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 27372.727% |
| ContraFect Corporation | -154 Thousand USD | 2048.052% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 6100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -3808.235% |
| IMV Inc. | -962.29 Thousand USD | 411.754% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 874.192% |
| MultiCell Technologies, Inc. | 49.32 USD | -6082625.061% |
| ONE Bio Corp. | 20.12 Million USD | 85.093% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 92.549% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -6034.969% |
| Q BioMed Inc. | -8988.00 USD | 33477.837% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 89.382% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 19550.207% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 93.237% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 362.796% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -4185.714% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 60681.583% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 3176.45% |
| GB Sciences, Inc. | -624.00 USD | 480869.231% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 3587.237% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 1442407.692% |
| Enzolytics Inc. | 30.7 Thousand USD | -9669.441% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -521.848% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.729% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 683.079% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -385.921% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.267% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 33975.339% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 3677.86% |
| Kadimastem Ltd | -630.13 Thousand USD | 576.086% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -203.65% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 25448.542% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -1599.139% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -121.053% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 10444.828% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -566.603% |
| SYBLEU INC | 11.69 Thousand USD | -25549.795% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 34.896% |
| Bioxytran, Inc. | -8285.00 USD | 36310.018% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 904.29% |
| Neutra Corp. | 14.33 Thousand USD | -20827.799% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 3758.537% |
| PureTech Health plc | -1.6 Million USD | 287.149% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 399.63% |
| IXICO plc | 3.27 Million USD | 8.257% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 532.277% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 267.504% |
| CSL Limited | 7.7 Billion USD | 99.961% |
| Cellectis S.A. | 18 Thousand USD | -16566.667% |